Kura and Kyowa’s Komzifti moves ahead at pace in US market
US biotech Kura Oncology (Nasdaq: KURA) and Japanese specialty pharma Kyowa Kirin (TYO: 4151) have secured early guideline recognition for Komzifti (ziftomenib), their new treatment for a subset of adults with relapsed or refractory acute myeloid leukemia.
Komzifti, the first and only once-daily oral menin inhibitor approved for adults with relapsed or refractory acute myeloid leukemia harboring a susceptible NPM1 mutation and no satisfactory alternatives, has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
The NCCN listing names Komzifti as a Category 2A recommended option for adults with relapsed or refractory acute myeloid leukemia and NPM1 mutation. The guidance arrives less than two weeks after the American medicines regulator granted full approval on November 13, 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze